Technical Expert - Ediscovery
About the job
- A bachelor's degree in Information Technology, Computer Science, or a related field.
- At least 5 years of hands-on experience in eDiscovery, digital forensics, or specialized IT incident response.
- Subject matter expert-level proficiency in Microsoft Purview, including designing, building, and executing end-to-end legally defensible search, preservation, and collection workflows across Microsoft 365.
- Hands-on experience with Relativity and modern cloud collection environments, including Google Workspace and Slack.
- Practical experience collecting electronically stored information across Apple iOS/macOS and Windows 10/11 environments.
- Basic experience handling FileVault and BitLocker encryption and using remote collection methodologies.
- Hands-on familiarity with Cellebrite UFED, Cellebrite Digital Collector, and Druva.
- Experience coordinating multiple functional areas and stakeholders while handling multiple priorities and projects accurately and professionally.
- Strong problem-solving skills and the ability to manage complex, time-sensitive priorities with precision, autonomy, and professionalism in an ambiguous, evolving environment.
- Exceptional communication skills and the ability to translate complex technical concepts into clear legal realities for legal counsel, human resources, compliance officers, and external forensic partners.
- Plan and execute legally defensible data preservation and collection strategies across the enterprise landscape.
- Perform forensic imaging on corporate iOS, macOS, and Windows laptops and mobile devices.
- Execute cloud-based eDiscovery through Microsoft Purview and retrieve case-critical data from internal systems globally.
- Manage eDiscovery review processes and execute advanced data processing within Relativity and Purview Premium.
- Prepare data for legal review by applying Boolean search strings, early case assessment, culling strategies, and technology-assisted review and artificial intelligence workflows.
- Oversee legal productions and drive continuous process and technology improvements.
- Execute time-sensitive data requests, physical evidence handling, and device collections across company systems.
- Establish and maintain standardized operating procedures, metric tracking, and detailed audit trails for preservation, collection, and processing tasks.
- Maintain a defensible chain of custody aligned with Electronic Discovery Reference Model standards.
- Oversee the operational readiness and end-to-end lifecycle of Microsoft Purview, Relativity, Cellebrite, and Druva.
- Manage software updates, troubleshoot issues, and optimize eDiscovery and forensic platforms for legal, compliance, and investigative needs.
- Evaluate and refine collection workflows for new operating system updates and emerging security features, including FileVault, BitLocker, and mobile device management profiles.
- Deploy workflow automation and artificial intelligence improvements.
- Contribute to the continuous improvement of legal and compliance data services.
- Develop and maintain relationships with legal and compliance stakeholders, the Roche Digital Technology group, and internal or external partners.
- Act as a liaison to eDiscovery and internal investigations teams and translate complex technical concepts into clear legal realities for legal and compliance teams and non-technical stakeholders.
- Experience in a highly regulated global industry such as pharmaceuticals, healthcare, or finance.
- Relativity Certified Administrator certification.
- Relevant forensic certifications such as CFCE, CCE, CCME, GCFE, or GCFA.
About the company
Roche is a global leader in pharmaceuticals and diagnostics. It develops medicines and diagnostic tools that help detect, monitor, and treat diseases, using research and biotechnology to drive new therapies and tests. Roche combines drug development with in-house diagnostic products to support personalized medicine, where treatments are tailored to individual patients based on test results. Its approach differs from many peers by integrating drug discovery with diagnostic capabilities and by expanding its research through strategic acquisitions (like Genentech) to strengthen its biotechnology and R&D capabilities. The company’s goal is to improve patient outcomes and healthcare worldwide by delivering reliable medicines, accurate diagnostic tests, and data-driven care.
Company Size
1-10
Company Stage
IPO
Headquarters
Basel, Switzerland
Founded
1896
Get referred to Roche
See people who can refer or advise you
Simplify's Take
What believers are saying
- Enicepatide delivered 15.5% weight loss in September 2026 and 22.7% in June.
- pTau217 can scale immediately through Roche's existing lab network and improve Alzheimer diagnostics.
- Roche's June 2026 data and September 2026 filings signal multiple obesity shots on goal.
What critics are saying
- Eli Lilly and Novo Nordisk dominate obesity pricing, distribution, and physician mindshare today.
- Enicepatide remains Phase II-only; Roche starts late-stage glycemic and cardiovascular studies in 2027.
- If enicepatide disappoints, Roche burns its $2.7 billion Carmot bet and loses obesity credibility.
What makes Roche unique
- Roche combines pharma, diagnostics, and installed cobas labs across 4,500 U.S. instruments.
- Elecsys pTau217 won FDA clearance on August 24, 2026, and CE marking September 7.
- Roche controls obesity assets from Carmot and Zealand, spanning GLP-1/GIP and amylin.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Performance Bonus
Company News
Roche posted strong Phase 2 results for its weight loss drug enicepatide, showing 22.5% mean weight loss over 48 weeks. This compares favourably to Eli Lilly's Zepbound, which achieved 20.2% weight loss over 72 weeks in a separate trial. In another Phase 2 study, enicepatide demonstrated HbA1c reductions of up to 2.65 percentage points in diabetic patients after 48 weeks, compared to tirzepatide's 2.37 percentage points after 52 weeks. Despite promising results, Roche faces stiff competition from Novo Nordisk and Eli Lilly, which both have deep pipelines in development. Novo Nordisk's CagriSema is nearing approval, whilst Eli Lilly's retatrutide has posted strong Phase 3 results. Roche's revenue grew 6% year over year in the first half of the year to 30.4 billion Swiss francs.
Roche has launched a newborn screening test that simultaneously detects three severe genetic conditions: Spinal Muscular Atrophy, Severe Combined Immunodeficiency Disease, and Sickle Cell Disease. TIB MOLBIOL, a Roche subsidiary, developed the LightMix Newborn TREC/SMN1/HBB kit for use in countries accepting the CE mark. The test enables early detection before symptoms appear, allowing clinicians to initiate life-changing treatments sooner. Early intervention can prevent severe nerve damage in SMA, enable lifesaving bone marrow transplants for SCID, and drastically lower infant mortality in SCD through preventive measures. The IVDR-approved test provides a ready-to-use solution that integrates into existing laboratory workflows. It runs on established LightCycler systems, making it accessible for private and academic hospital laboratories across Europe.
Roche's collaborator MediLink has announced positive phase III results for tambotatug pelitecan (Tam-Peli) in Chinese patients with relapsed small-cell lung cancer. The TAISHAN-302 trial showed Tam-Peli reduced the risk of death by 54% compared to topotecan, with median overall survival of 13.3 versus 9.4 months. The antibody-drug conjugate also demonstrated superior progression-free survival (7.4 versus 2.8 months) and objective response rates (59.1% versus 9.7%). China's National Medical Products Administration has accepted the New Drug Application for filing. Roche is developing and commercialising Tam-Peli outside mainland China, Hong Kong and Macau, with plans to rapidly initiate global trials. The therapy has received Breakthrough Therapy Designations from both the US FDA and China CDE for relapsed small-cell lung cancer.
Tempus AI has raised $600 million in Series C funding to scale its machine learning platform for cancer recurrence detection through liquid biopsies. The investment was led by SoftBank Vision Fund 2, with participation from Roche and Merck. Phase II trial data showed the AI-enhanced liquid biopsy analysis reduced false-negative results by 37% compared to conventional methods. The platform uses deep learning algorithms trained on over 12,000 genomic profiles to identify circulating tumour DNA fragments shed by residual cancer cells. A 2025 Nature Medicine study reported the system achieved 92% specificity in detecting minimal residual disease across breast, lung, and colorectal cancers. According to SEC filings, 45% of funds will support FDA pre-market approval trials, whilst 30% will fund global expansion into EU and APAC markets.
Roche has committed $75 million upfront to acquire global rights to Simcere Pharmaceutical's experimental blood-cancer drug SIM0660. The deal could reach $1.53 billion if the drug meets development, regulatory and commercial milestones, with additional tiered royalties. The agreement grants Roche exclusive development, manufacturing and commercialisation rights outside Simcere's retained markets. The upfront payment represents just 4.9% of the deal's total potential value. SIM0660 remains in preclinical stages. Roche generated CHF11.9 billion in core operating profit during the first half of the year. The company's US-quoted shares fell to $53.55 on Tuesday following the announcement.